{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:15:05Z","timestamp":1787620505783,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.ejmech.2013.05.007","type":"journal-article","created":{"date-parts":[[2013,5,16]],"date-time":"2013-05-16T05:16:05Z","timestamp":1368681365000},"page":"450-465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis"],"prefix":"10.1016","volume":"66","author":[{"given":"Lori","family":"Ferrins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Rahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky M.","family":"Avery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliott","family":"Teston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basmah","family":"Almohaywi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JieXiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Charman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan B.","family":"Baell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2013.05.007_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human African trypanosomiasis","volume":"375","author":"Brun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2013.05.007_bib2","unstructured":"WHO, Human African trypanosomiasis, http:\/\/www.who.int\/trypanosomiasis_african\/en\/ (accessed 30.07.12)."},{"key":"10.1016\/j.ejmech.2013.05.007_bib3","unstructured":"WHO, Drugs, http:\/\/www.who.int\/trypanosomiasis_african\/drugs\/en\/index.html (accessed 27.07.12)."},{"key":"10.1016\/j.ejmech.2013.05.007_bib4","first-page":"177","article-title":"Recent research on the biological activity of suramin","volume":"45","author":"Voogd","year":"1993","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2013.05.007_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0020-7519(01)00167-9","article-title":"Transporters in African trypanosomes: role in drug action and resistance","volume":"31","author":"de Koning","year":"2001","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ejmech.2013.05.007_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00436-002-0799-9","article-title":"Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis","volume":"90","author":"Nok","year":"2003","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ejmech.2013.05.007_bib7","series-title":"Antimicrobial Drug Resistance","first-page":"589","article-title":"Drug resistance in African trypanosomiasis","author":"Seebeck","year":"2009"},{"key":"10.1016\/j.ejmech.2013.05.007_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2013.05.007_bib9","unstructured":"DNDi, Oxaborole SCYX-7158 (HAT), http:\/\/www.dndi.org\/portfolio\/oxaborole-scyx-7158.html (accessed 27.07.12)."},{"key":"10.1016\/j.ejmech.2013.05.007_bib10","unstructured":"DNDi, Pivotal study of fexinidazole for human African trypanosomiasis in\u00a0stage 2, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01685827?term=fexinidazole&rank=3#wrapper (accessed 23.11.12)."},{"key":"10.1016\/j.ejmech.2013.05.007_bib11","doi-asserted-by":"crossref","first-page":"e1896","DOI":"10.1371\/journal.pntd.0001896","article-title":"Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS Campaign","volume":"6","author":"Sykes","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejmech.2013.05.007_bib12","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1471-4159.2008.05706.x","article-title":"The blood\u2013brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain","volume":"107","author":"Sanderson","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2013.05.007_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000961","article-title":"Phylogeography and taxonomy of Trypanosoma brucei","volume":"5","author":"Balmer","year":"2011","journal-title":"PLoS Negl Trop. Dis."},{"key":"10.1016\/j.ejmech.2013.05.007_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.ejmech.2013.05.007_bib15","doi-asserted-by":"crossref","unstructured":"J.-R. Ioset, Natural products for neglected diseases: a review, Curr. Org. Chem. 12, 643\u2013666.","DOI":"10.2174\/138527208784577394"},{"key":"10.1016\/j.ejmech.2013.05.007_bib16","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole \u2013 a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"Torreele","year":"2010","journal-title":"PLoS Negl Trop. Dis."},{"key":"10.1016\/j.ejmech.2013.05.007_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/1389200054021799","article-title":"A\u00a0comprehensive listing of bioactivation pathways of organic functional groups","volume":"6","author":"Kalgutkar","year":"2005","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejmech.2013.05.007_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/978-0-387-77570-8_5","article-title":"Fishing for anti-leishmania\u00a0drugs: principles and problems","volume":"625","author":"Handman","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2013.05.007_bib19","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.bmcl.2008.11.106","article-title":"Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators","volume":"19","author":"Bemis","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2013.05.007_bib20","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1074\/jbc.M707613200","article-title":"Acetylation-dependent ADP-ribosylation by Trypanosoma brucei Sir2","volume":"283","author":"Kowieski","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2013.05.007_bib21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2958.2006.05553.x","article-title":"A\u00a0sirtuin in the African trypanosome is involved in both DNA repair and telomeric gene silencing but is not required for antigenic variation","volume":"63","author":"Alsford","year":"2007","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2013.05.007_bib22","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3987\/COM-95-7245","article-title":"Synthesis of 6-Substituted 2-phenyloxazolo[4,5-b]pyridines","volume":"41","author":"Viaud","year":"1995","journal-title":"Heterocycles"},{"key":"10.1016\/j.ejmech.2013.05.007_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jhet.5570260205","article-title":"Aminophenyl-X-azolopyridines as precursors of heterocyclic azo dyes","volume":"26","author":"Savarino","year":"1989","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2013.05.007_bib24","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/ac9912247","article-title":"A\u00a0high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates","volume":"72","author":"Bevan","year":"2000","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2013.05.007_bib25","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1021\/jm0100990","article-title":"ElogDoct:\u2009 a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds","volume":"44","author":"Lombardo","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2013.05.007_bib26","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/jps.10494","article-title":"Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol\/water and immobilized artificial membrane lipophilicity","volume":"92","author":"Valko","year":"2003","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.ejmech.2013.05.007_bib27","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in\u00a0vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2013.05.007_bib28","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2013.05.007_bib29","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/AAC.16.6.710","article-title":"Quantitative assessment of antimalarial activity in\u00a0vitro by a semiautomated microdilution technique","volume":"16","author":"Desjardins","year":"1979","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2013.05.007_bib30","series-title":"Immunological Methods","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-442704-4.50021-9","article-title":"Plasmodium falciparum malaria parasite cultures and their use in immunology","author":"Matile","year":"1990"},{"key":"10.1016\/j.ejmech.2013.05.007_bib31","first-page":"50","article-title":"Chloroquine sensitivity of isolates of Plasmodium falciparum adapted to in\u00a0vitro culture","volume":"33","author":"Ponnudurai","year":"1981","journal-title":"Trop. Geogr. Med."},{"key":"10.1016\/j.ejmech.2013.05.007_bib32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0001-706X(93)90083-N","article-title":"A\u00a0comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites","volume":"55","author":"Huber","year":"1993","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2013.05.007_bib33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1432-1033.1995.tb20583.x","article-title":"Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials","volume":"230","author":"Cunningham","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2013.05.007_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1383-5769(99)00020-3","article-title":"A\u00a0simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue\u00ae","volume":"48","author":"Mikus","year":"2000","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.ejmech.2013.05.007_bib35","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1128\/AAC.40.11.2592","article-title":"Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase","volume":"40","author":"Buckner","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2013.05.007_bib36","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/j.1460-2075.1985.tb03772.x","article-title":"Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T.\u00a0equiperdum, T.\u00a0evansi, T.\u00a0rhodesiense and T.\u00a0gambiense","volume":"4","author":"Baltz","year":"1985","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2013.05.007_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0001-706X(97)00079-X","article-title":"The Alamar Blue\u00ae assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in\u00a0vitro","volume":"68","author":"R\u00e4z","year":"1997","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2013.05.007_bib38","first-page":"473","article-title":"A\u00a0new fluorometric assay for cytotoxicity measurements in\u00a0vitro","volume":"3","author":"Page","year":"1993","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2013.05.007_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0022-1759(94)90396-4","article-title":"A\u00a0new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay","volume":"170","author":"Ahmed","year":"1994","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.ejmech.2013.05.007_bib40","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4269\/ajtmh.2009.09-0015","article-title":"Development of an Alamar Blue\u2122 viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427","volume":"81","author":"Sykes","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2013.05.007_bib41","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2307\/3282883","article-title":"Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers","volume":"75","author":"Hirumi","year":"1989","journal-title":"J.\u00a0Parasitol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523413003073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523413003073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T10:19:12Z","timestamp":1746008352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523413003073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":41,"alternative-id":["S0223523413003073"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2013.05.007","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2013.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}